Diseases of cardiovascular system in patients with moderate-to-severe and severe forms of psoriasis
https://doi.org/10.33667/2078-5631-2021-34-35-38
Abstract
Psoriasis is one of the most common chronic immune-mediated skin diseases. One of the widely discussed gastroenterological comorbidities of psoriasis is chronic inflammatory diseases of the gastrointestinal tract. The article presents the results of the analysis of the case histories of patients with moderate-to-severe and severe forms of psoriasis and concomitant pathology – inflammatory bowel diseases (Clinical Dermatovenerologic Dispensary, Krasnodar, Russia). The analysis of 16 case histories of patients with moderate-to-severe and severe psoriasis has been carried out, where one can see the clinical and practical significance of the combined pathology – psoriasis and inflammatory bowel diseases. From the analysis, one can conclude that there is a direct relationship between the severity of the course of the skin pathological process and the development of intestinal diseases, as well as the influence of ustekinumab on the course of combined pathology – psoriasis, ulcerative colitis and Crohn’s disease.
About the Authors
A. A. Hotko
Clinical Dermatovenerologic Dispensary
Russian Federation
Russian Federation
Hotko Alkes A., PhD Med, associate professor, deputy chief physician
Krasnodar
M. Yu. Pomazanova
Clinical Dermatovenerologic Dispensary
Russian Federation
Russian Federation
Pomazanova Marina Yu., head of Women’s Inpatient Dept
Krasnodar
M. V. Durleshter
Regional Clinical Hospital No. 2
Russian Federation
Russian Federation
Durleshter Marina V., ultrasound diagnostician
Krasnodar
References
1. Aaron E. Walfish, MD, Mount Sinai Medical Center; Rafael Antonio Ching Companioni, MD, Digestive Diseases Center.
2. Shapina M. V., Nanaeva B. A., Vardanyan A. V. Efficacy and safety of ustekinumab in Crohn’s disease (literature review). Coloproctology. 2019; Vol. 18, No. 3 (69), pp. 119–130.
3. Elder J. T., Bruce A. T., Gudjonsson J. E. et al. Molecular dissection of psoriasis: integrating genetics and biology. J. Invest. Dermatol. 2010. Vol. 130. No. 5. P. 1213–1226.
4. Onishi RM, Gaffen SL. Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease. Immunology. 2010; 129 (3): 311–21. DOI: 10.1111/j.1365–2567.2009.03240.x.
5. Macaluso F. S., Orlando A., Cottone M. Anti-interleukin-12 and antiinterleukin-23 agents in Crohn’s disease. Exp Opin Biol Ther. 2019; 19 (2): 89–98. DOI: 10.1080/14712598.2019.1561850.
6. Feagan B. G., Sandborn W. J., Gasink C., Jacobstein D., Lang Y., Friedman J. R. et al. Ustekinumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2016; 375 (20): 1946–1960. DOI: 10.1056/NEJMoa1602773.
7. Hanauer S. B., Sandborn W. J., Feagan B. G., Gasink C., Jacobstein D., Zou B. et al. IM-UNITI: Three-year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn’s Disease. J Crohns Colitis. 2020; 14 (1): 23–32. DOI: 10.1093/ecco-jcc/jjz110.
8. McInnes I.B., Kavanaugh A., Gottlieb A. B., Puig L., Rahman P., Ritchlin C. et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1-year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet. 2013; 382 (9894): 780–789. DOI: 10.1016/S0140–6736(13)60594–2.
9. Ritchlin C., Rahman P., Kavanaugh A., McInnes I.B., Puig L., Li S. et al. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis. 2014; 73 (6): 990–999. DOI: 10.1136/annrheumdis-2013–204655.
10. Kavanaugh A, Ritchlin C, Rahman P, Puig L, et al. Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: Results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT‑2 trials. Ann Rheum Dis. 2014; 73: 1000–1006.
11. Toichi E, Torres G, McCormick TS, Chang T, et al. An anti-IL12p40 antibody down-regulates type 1 cytokines, chemokines, and IL-12/IL-23 in psoriasis. J Immunol. 2006; 177: 4917–4926.
12. Peluso I, Pallone F, Monteleone G. Interleukin-12 and Th1 immune response in Crohn’s disease: Pathogenetic relevance and therapeutic implication. World J Gastroenterol. 2006; 12: 5606–5610.
13. Siakavellas SI, Bamias G. Role of the IL-23/IL-17 axis in Crohn’s disease. Discov Med. 2012; 14: 253–262. 28. Cote-Daigneault J, Bouin M, Lahaie R, Colombel JF, Poitras P.
14. Kruglova L. S., Lvov A. N., Kagramanova A. V., Knyazev O. V. Psoriasis and inflammatory bowel diseases: pathogenesis pathways and questions of the choice of genetically engineered drugs (literature review). Almanac of Clinical Medicine. 2019. No. 6.
Review
For citations:
Hotko A.A., Pomazanova M.Yu., Durleshter M.V. Diseases of cardiovascular system in patients with moderate-to-severe and severe forms of psoriasis. Medical alphabet. 2021;(34):35-38. (In Russ.) https://doi.org/10.33667/2078-5631-2021-34-35-38
Views:
334
Email this article 